DGAP-Adhoc

Supervisory Board of Epigenomics AG appoints Gregory Hamilton as Chief Executive Officer (CEO)

Epigenomics AG / Key word(s): Change of Personnel

30.06.2016 21:17

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act)

Supervisory Board of Epigenomics AG appoints Gregory Hamilton as Chief
Executive Officer (CEO)

Berlin, Germany, June 30, 2016 - The Supervisory Board of Epigenomics AG,
Berlin, Germany (Frankfurt Prime Standard: ECX, ISIN: DE0000A11QW50) has
today appointed Gregory Hamilton as Chief Executive Officer with effect
from July 1, 2016. Mr. Hamilton, who has held senior management positions
in the U.S. molecular diagnostics industry, will succeed Dr. Thomas Taapken
who has today resigned from his office.

Mr. Hamilton, (46), has over 20 years of management experience in molecular
diagnostics, manufacturing and professional service industries. Prior to
joining Epigenomics, Mr. Hamilton was Chief Executive Officer & Director of
AltheaDx Inc., Chief Operating Officer and Chief Financial Officer of
Enigma Diagnostics Inc., Vice President of Operations and Finance at Third
Wave Technologies Inc. and Vice President of Operations at Hologic Inc. He
has been responsible for multiple FDA-cleared products including a Human
Papilloma Virus (HPV) High Risk Screening assay and the first ever cleared
HPV genotyping assay. Mr. Hamilton received his MBA from the University of
Chicago and his Bachelor of Science in Finance from Purdue University.

Dr. Thomas Taapken, who has served in the dual role of CEO and CFO since
2012, will leave the company with effect of today. The Supervisory Board
expressed its great appreciation for Dr. Taapken's outstanding
contributions to the development of the company. The Supervisory Board
wishes Dr. Taapken all the best for the future.

The vacant CFO position will be filled shortly.

- end of ad-hoc-

Contact Epigenomics AG

Peter Vogt
VP Corporate Communications & Investor Relations
Geneststraße 5
10829 Berlin
Phone [phone]
[e-mail]

http://www.epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such forward-
looking statements. Epigenomics AG is providing this communication as of
this date and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or
otherwise.


30.06.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.epigenomics.com
ISIN: DE000A11QW50
WKN: A11QW5
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------